GlassScriptPhysician profile
Udit Yadav
NPI 1750721932
$3,058.03
in general payments reported to CMS, 2019-2025
33 companies · $43.25 in 2025
The $43.25 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $538 · 2020: $1,109 · 2021: $833 · 2022: $534 · 2025: $43.25.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $43.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $43.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $807.85 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $360.45 | 2019-2025 | Enhertu |
| Pfizer INC. | $251.40 | 2019-2022 | |
| Amgen INC. | $234.94 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $149.23 | 2019-2020 | |
| Pharmacyclics LLC, An Abbvie Company | $117.32 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $102.31 | 2020-2022 | |
| Seagen INC. | $94.14 | 2019-2022 | |
| Genzyme Corporation | $88.54 | 2020-2022 | |
| Jazz Pharmaceuticals INC. | $77.07 | 2021 | |
| Daiichi Sankyo INC. | $71.02 | 2019-2020 | |
| Deciphera Pharmaceuticals INC. | $62.14 | 2021-2022 | |
| Clovis Oncology, INC. | $58.63 | 2019-2020 | |
| Eisai INC. | $56.69 | 2019-2021 | |
| Incyte Corporation | $50.90 | 2020-2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Octapharma USA, INC. | $49.05 | 2020 | |
| Alexion Pharmaceuticals, INC. | $48.77 | 2019-2020 | |
| Celgene Corporation | $45.87 | 2022 | |
| Lilly USA, LLC | $40.19 | 2019-2021 | |
| Dova Pharmaceuticals | $37.63 | 2020 | |
| Janssen Scientific Affairs, LLC | $28.98 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $26.48 | 2020-2021 | |
| Exelixis INC. | $25.34 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.27 | 2019 | |
| Tg Therapeutics, INC. | $19.96 | 2021 | |
| Eusa Pharma (US) LLC | $19.25 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $18.72 | 2019 | |
| Karyopharm Therapeutics INC. | $18.71 | 2021 | |
| Array Biopharma INC | $16.59 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $15.83 | 2020 | |
| Janssen Biotech, INC. | $15.83 | 2020 | |
| Glaxosmithkline, LLC. | $14.04 | 2020 | |
| Kyowa Kirin, INC. | $13.89 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Udit Yadav listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.